Your browser doesn't support javascript.
Exploiting Ubiquitin Ligases for Induced Target Degradation as an Antiviral Strategy.
Verma, Rati.
  • Verma R; AMGEN Research, One Amgen Center Drive, Thousand Oaks, CA, USA. rverma03@amgen.com.
Adv Exp Med Biol ; 1322: 339-357, 2021.
Article in English | MEDLINE | ID: covidwho-1353665
ABSTRACT
Posttranslational modifications of targeted substrates alter their cellular fate. Ubiquitin is a highly conserved and ubiquitous covalent modifier protein that tags substrates with a single molecule or with a polyubiquitin chain. Monoubiquitination affects trafficking and signaling patterns of modified proteins. In contrast, polyubiquitination, particularly K48-linked polyubiquitination, targets the protein for degradation by the Ubiquitin-Proteasome System (UPS) resulting in a committed fate through irreversible inactivation of substrate. Given the diversity of cellular functions impacted by ubiquitination, it is no surprise that the wily pathogenic viruses have co-opted the UPS in myriad ways to ensure their survival. In this review, I describe viral exploitation of nondegradative ubiquitin signaling pathways to effect entry, replication, and egress. Additionally, viruses also harness the UPS to degrade antiviral cellular host factors. Finally, I describe how we can exploit the same proteolytic machinery to enable PROTACs (Proteolysis-Targeting Chimeras) to degrade essential viral proteins. Successful implementation of this modality will add to the arsenal of emerging antiviral therapies.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Ubiquitin Type of study: Prognostic study Language: English Journal: Adv Exp Med Biol Year: 2021 Document Type: Article Affiliation country: 978-981-16-0267-2_13

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Ubiquitin Type of study: Prognostic study Language: English Journal: Adv Exp Med Biol Year: 2021 Document Type: Article Affiliation country: 978-981-16-0267-2_13